← Back to Search

Regenecare® Wound Gel for Rash from Cancer Therapy

N/A
Waitlist Available
Research Sponsored by Ingalls Memorial Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Starting treatment with cetuximab or other EGFR inhibitor (e.g., erlotinib hydrochloride) on another clinical trial
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying a treatment for acne-like rash caused by cetuximab or another epidermal growth factor receptor inhibitor.

Who is the study for?
This trial is for cancer patients starting treatment with cetuximab or other EGFR inhibitors. It's not for those who are pregnant, nursing, using other facial creams, or have serious skin conditions like scleroderma or psoriasis that could affect rash assessment.Check my eligibility
What is being tested?
The study is testing Regenecare® wound gel to see if it can relieve pain and itching from acne-like rashes caused by cancer treatments targeting the epidermal growth factor receptor.See study design
What are the potential side effects?
Potential side effects of Regenecare® wound gel may include reactions in patients with known hypersensitivity to amine-type local anesthetics or its components.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am starting treatment with an EGFR inhibitor like cetuximab.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching
Secondary outcome measures
Efficacy of Regenecare® wound gel, in terms of reducing severity, redness, and appearance of rash
Tolerability of Regenecare® wound gel as assessed by NCI CTCAE v3.0

Find a Location

Who is running the clinical trial?

Ingalls Memorial HospitalLead Sponsor
Mark F. Kozloff, MDStudy ChairIngalls Memorial Hospital

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00498992 — N/A
Skin Complications Research Study Groups:
Skin Complications Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00498992 — N/A
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00498992 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers currently seeking out participants for this clinical trial?

"Clinicaltrials.gov reveals that this clinical trial has not been actively seeking patients since September 19th 2013, although it was initially posted on July 1st 2006. Nonetheless, 42 other trials are currently recruiting participants at present."

Answered by AI
~1 spots leftby Mar 2025